KDR rs2071559	Renal Cell Carcinoma	KDR rs2071559	Renal Cell Carcinoma	sunitinib Sensitive: B - Late Trials sunitinib Sensitive : B	sunitinib Sensitive: B - Late Trials sunitinib Sensitive : B
KDR rs2305945	Ovarian Cancer	KDR rs2305945	Ovarian Cancer	bevacizumab Resistant: B - Late Trials bevacizumab Resistant : B	bevacizumab Resistant: B - Late Trials bevacizumab Resistant : B
MET overexpression + KDR overexpression	Ovarian Cancer	MET overexpression + KDR overexpression	Ovarian Cancer	bevacizumab Resistant: B - Late Trials bevacizumab Resistant : B	bevacizumab Resistant: B - Late Trials bevacizumab Resistant : B
KDR V297L	Colorectal Cancer	KDR V297L	Colorectal Cancer	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3
KDR elevation	Hepatocellular Cancer	KDR elevation	Hepatocellular Cancer	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3
KDR expression	Esophageal Squamous Cell Carcinoma	KDR expression	Esophageal Squamous Cell Carcinoma	rivoceranib Sensitive: C3 – Early Trials rivoceranib Sensitive : C3	rivoceranib Sensitive: C3 – Early Trials rivoceranib Sensitive : C3
KDR overexpression	Glioblastoma	KDR overexpression	Glioblastoma	bevacizumab + erlotinib Resistant: C3 – Early Trials bevacizumab + erlotinib Resistant : C3	bevacizumab + erlotinib Resistant: C3 – Early Trials bevacizumab + erlotinib Resistant : C3
KDR overexpression	Hepatocellular Cancer	KDR overexpression	Hepatocellular Cancer	bevacizumab + atezolizumab Sensitive: C3 – Early Trials bevacizumab + atezolizumab Sensitive : C3	bevacizumab + atezolizumab Sensitive: C3 – Early Trials bevacizumab + atezolizumab Sensitive : C3
KDR mutation	Non Small Cell Lung Cancer	KDR mutation	Non Small Cell Lung Cancer	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3
KDR Q472H	Melanoma	KDR Q472H	Melanoma	dabrafenib + lenvatinib Sensitive: C3 – Early Trials dabrafenib + lenvatinib Sensitive : C3	dabrafenib + lenvatinib Sensitive: C3 – Early Trials dabrafenib + lenvatinib Sensitive : C3
KDR expression	Renal Cell Carcinoma	KDR expression	Renal Cell Carcinoma	sunitinib Sensitive: C3 – Early Trials sunitinib Sensitive : C3	sunitinib Sensitive: C3 – Early Trials sunitinib Sensitive : C3
VEGFA expression + FLT1 expression + KDR expression	Colorectal Cancer	VEGFA expression + FLT1 expression + KDR expression	Colorectal Cancer	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3

KDR (Kinase insert domain receptor)

Associations(34)

Associations
(34)